SAE1 and B-cell non-Hodgkin lymphoma: In 2012, an unbiased genetic screen demonstrated the synthetic lethality of the SUMO pathway components SAE1 and SAE2 with MYC,64 an observation subsequently corroborated in haematological malignancies89 and small cell lung cancer (SCLC).90 Across species, MYC-driven B cell lymphomas were characterised to upregulate core components of the SUMOylation machinery, including SUMO proteins, SAE1, SAE2, and UBC9.